Supplemental Table 2 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial

Supplemental Table 2: All adverse events among those patients who discontinued ANA1 early or did not continue onto ANA10 after IES finding due to toxicity.